Top

Thrombosis Journal

Published in:

Open Access 01-12-2023 | Phlebothrombosis | Review

Association between inflammatory biomarkers and venous thromboembolism: a systematic review and meta-analysis

Authors: Jiayue Ding, Xuanye Yue, Xiaobing Tian, Zhangyuan Liao, Ran Meng, Ming Zou

Published in: Thrombosis Journal | Issue 1/2023

Abstract

Background

Venous thromboembolism (VTE) is a common thrombotic vascular disease that has a significant impact on people’s well-being and quality of life. A plethora of clinical studies explore the relationship between inflammatory biomarkers and VTE but yield conflicting results. This article proposed to pool these studies to draw a more convincing conclusion.

Methods

We searched several databases for studies before April 2023. Available data was processed using Stata software (version 15.0 SE) and R (version 4.1.2). This meta-analysis has been registered in PROSPERO (CRD42022321815). The VTE in this review encompassed pulmonary embolism, deep vein thrombosis, and cerebral venous thrombosis.

Results

A total of 25 articles were finally involved in this study. Our results revealed that higher levels of high-sensitivity C-reactive protein (hs-CRP, MD, 0.63, 95%CI, 0.21—1.05) and C-reactive protein (CRP)> 3ug/ml (OR, 1.52, 95%CI, 1.18—1.96) might be regarded as risk factors for future VTE occurrence. The elevated levels of monocyte (MD, 0.03, 95%CI, 0.00—0.05), hs-CRP (0.85, 0.61—1.08), CRP (0.66, 0.20—1.13) and IL-6 (0.47, 0.25—0.70) might represent the previous VTE; a series of markers such as white blood cell (1.43, 0.88—1.98), neutrophil (1.79, 1.02—2.56), monocyte (0.17, 0.14—0.21), hs-CRP (3.72, 1.45—5.99), IL−6 (5.99, 4.52—7.46), platelet-lymphocyte ratio (33.1, 24.45—41.78) and neutrophil-lymphocyte ratio (1.34, 0.95—1.73) increased during the acute phase of VTE.

Conclusions

In general, activated inflammatory biomarkers might not only be correlated with an increased risk of VTE, but may also give a hint of the occurrence of VTE in clinical settings.

Available only for authorised users

Silverstein MD, Heit JA, Mohr DN, Petterson TM, O&#39, Fallon WM, Melton LJ 3rd: Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch. Intern. Med. 1998, 158:585–593.

Riva N, Donadini MP, Ageno W. Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation. Thromb Haemost. 2015;113:1176–83.PubMedCrossRef

Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost. 2005;94:362–5.PubMedCrossRef

Saghazadeh A, Hafizi S, Rezaei N. Inflammation in venous thromboembolism: cause or consequence. Int Immunopharmacol. 2015;28:655–65.PubMedCrossRef

Ding J, Song B, Xie X, Li X, Chen Z, Wang Z, Pan L, Lan D, Meng R. Inflammation in cerebral venous thrombosis. Front Immunol. 2022;13:833490.PubMedPubMedCentralCrossRef

van Aken BE, den Heijer M, Bos GM, van Deventer SJ, Reitsma PH. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost. 2000;83:536–9.PubMedCrossRef

Etulain J, Martinod K, Wong SL, Cifuni SM, Schattner M, Wagner DD. P-selectin promotes neutrophil extracellular trap formation in mice. Blood. 2015;126:242–6.PubMedPubMedCentralCrossRef

Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34–45.PubMedCrossRef

von Brühl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, Khandoga A, Tirniceriu A, Coletti R, Köllnberger M, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209:819–35.CrossRef

10.

Tichelaar YI, Kluin-Nelemans HJ, Meijer K. Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb Haemost. 2012;107:827–37.PubMedCrossRef

11.

Silvis SM, de Sousa DA, Ferro JM, Coutinho JM. Cerebral venous thrombosis. Nat Rev Neurol. 2017;13:555–65.PubMedCrossRef

12.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg (London England). 2010;8:336–41.CrossRef

13.

Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol. 2010;30:1672–8.PubMedCrossRef

14.

Olson NC, Cushman M, Lutsey PL, McClure LA, Judd S, Tracy RP, Folsom AR, Zakai NA. Inflammation markers and incident venous thromboembolism: the REasons for Geographic and racial differences in stroke (REGARDS) cohort. J Thromb Haemost. 2014;12:1993–2001.PubMedPubMedCentralCrossRef

15.

Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 2002;113:636–42.PubMedCrossRef

16.

Folsom AR, Lutsey PL, Heckbert SR, Poudel K, Basu S, Hoogeveen RC, Cushman M, Ballantyne CM. Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism. J Thromb Haemost. 2018;16:1964–72.PubMedPubMedCentralCrossRef

17.

Rattazzi M, Villalta S, Galliazzo S, Del Pup L, Sponchiado A, Faggin E, Bertacco E, Buso R, Seganfreddo E, Pagliara V, et al. Low CD34(+) cells, high neutrophils and the metabolic syndrome are associated with an increased risk of venous thromboembolism. Clin Sci (London England: 1979). 2013;125:211–8.CrossRef

18.

Artoni A, Abbattista M, Bucciarelli P, Gianniello F, Scalambrino E, Pappalardo E, Peyvandi F, Martinelli I. Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio as risk factors for venous thrombosis. Clin Appl Thromb Hemost. 2018;24:808–14.PubMedCrossRef

19.

Yang W, Liu Y. Platelet-lymphocyte ratio is a predictor of venous thromboembolism in cancer patients. Thromb Res. 2015;136:212–5.PubMedCrossRef

20.

Poredos P, Jezovnik MK. In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction. Heart Vessels. 2011;26:596–602.PubMedCrossRef

21.

Vormittag R, Vukovich T, Schönauer V, Lehr S, Minar E, Bialonczyk C, Hirschl M, Pabinger I. Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism. Thromb Haemost. 2005;93:488–93.PubMedCrossRef

22.

Matos MF, Lourenço DM, Orikaza CM, Bajerl JA, Noguti MA, Morelli VM. The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6 -174GC, IL-8 -251AT and MCP-1 -2518AG in the risk of venous thromboembolism: a case-control study. Thromb Res. 2011;128:216–20.PubMedCrossRef

23.

Luxembourg B, Schmitt J, Humpich M, Glowatzki M, Dressler D, Seifried E, Lindhoff-Last E. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: a focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP). Thromb Haemost. 2009;102:668–75.PubMedCrossRef

24.

Farah R, Nseir W, Kagansky D, Khamisy-Farah R. The role of neutrophil-lymphocyte ratio, and mean platelet volume in detecting patients with acute venous thromboembolism. J Clin Lab Anal. 2020;34:e23010.PubMedCrossRef

25.

Bakirci EM, Topcu S, Kalkan K, Tanboga IH, Borekci A, Sevimli S, Acikel M. The role of the nonspecific inflammatory markers in determining the anatomic extent of venous thromboembolism. Clin Appl Thromb Hemost. 2015;21:181–5.PubMedCrossRef

26.

Reiter M, Bucek RA, Koca N, Dirisamer A, Minar E. Deep vein thrombosis and systemic inflammatory response: a pilot trial. Wien Klin Wochenschr. 2003;115:111–4.PubMedCrossRef

27.

Zakai NA, Callas PW, Repp AB, Cushman M. Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study. J Thromb Haemost. 2013;11:634–41.PubMedCrossRef

28.

Ming L, Jiang Z, Ma J, Wang Q, Wu F, Ping J. Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and platelet indices in patients with acute deep vein thrombosis. VASA Z fur Gefasskrankheiten. 2018;47:143–7.CrossRef

29.

Kurtipek E, Büyükterzi Z, Büyükterzi M, Alpaydın MS, Erdem SS. Endothelial dysfunction in patients with pulmonary thromboembolism: neutrophil to lymphocyte ratio and platelet to lymphocyte ratio. Clin Respir J. 2017;11:78–82.PubMedCrossRef

30.

Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost. 2004;2:2156–61.PubMedCrossRef

31.

Ramacciotti E, Blackburn S, Hawley AE, Vandy F, Ballard-Lipka N, Stabler C, Baker N, Guire KE, Rectenwald JE, Henke PK, et al. Evaluation of soluble P-selectin as a marker for the diagnosis of deep venous thrombosis. Clin Appl Thromb Hemost. 2011;17:425–31.PubMedCrossRef

32.

Kamisli S, Kamisli O, Gonullu S, Kaplan Y, Ozcan C. The prognostic value of increased leukocyte and neutrophil counts in the early phase of cerebral venous sinus thrombosis. Turk Serebrovaskuler Hastaliklar Dergisi. 2012;18:35–8.

33.

Wang L, Duan J, Bian T, Meng R, Wu L, Zhang Z, Zhang X, Wang C, Ji X. Inflammation is correlated with severity and outcome of cerebral venous thrombosis. J Neuroinflammation. 2018;15:329.PubMedPubMedCentralCrossRef

34.

Tekesin A, Tunç A. Inflammatory markers are beneficial in the early stages of cerebral venous thrombosis. Arq Neuropsiquiatr. 2019;77:101–5.PubMedCrossRef

35.

Zhou L, Mao Y, Wang L, Jiang J, Xu W, Xu J, Song H. Comparison of peripheral blood T lymphocyte immune function among venous thromboembolism patients with and without infection and patients with simple infection. Int J Clin Exp Med. 2015;8:6585–91.PubMedPubMedCentral

36.

Lowe G, Rumley A, Woodward M, Vessey M. C-reactive protein, idiopathic venous thromboembolism and hormone replacement therapy. Thromb Haemost. 2000;84:730–1.PubMedCrossRef

37.

Akboga YE, Bektas H, Anlar O. Usefulness of platelet to lymphocyte and neutrophil to lymphocyte ratios in predicting the presence of cerebral venous sinus thrombosis and in-hospital major adverse cerebral events. J Neurol Sci. 2017;380:226–9.PubMedCrossRef

38.

Zhou L, Song H, Xu W, Xu J, Jiang J, Gong Z, Liu Y, Yan W, Wang L. Immune function of peripheral T cells in patients with venous thromboembolism or coronary artery atherosclerosis. Revista portuguesa de cardiologia: orgao oficial da sociedade portuguesa de cardiologia = portuguese. J Cardiol : official J Portuguese Soc Cardiol. 2014;33:339–44.

39.

Xu G, Liu X, Zhu W, Yin Q, Zhang R, Fan X. Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention. Blood Coagul Fibrinolysis. 2007;18:193–7.PubMedCrossRef

40.

Gómez-Hernández A, Sánchez-Galán E, Martín-Ventura JL, Vidal C, Blanco-Colio LM, Ortego M, Vega M, Serrano J, Ortega L, Hernández G, et al. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization. J Cardiovasc Pharmacol. 2006;47:60–9.PubMedCrossRef

41.

Yaron G, Brill A, Dashevsky O, Yosef-Levi IM, Grad E, Danenberg HD, Varon D. C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis. Br J Haematol. 2006;134:426–31.PubMedCrossRef

42.

Venugopal SK, Devaraj S, Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation. 2003;108:1676–8.PubMedCrossRef

43.

Vazquez-Garza E, Jerjes-Sanchez C, Navarrete A, Joya-Harrison J, Rodriguez D. Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. J Thromb Thrombolysis. 2017;44:377–85.PubMedCrossRef

44.

Jerjes-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease. Eur Heart J. 2005;26:3–4.PubMedCrossRef

45.

Kelly PJ, Lemmens R, Tsivgoulis G. Inflammation and stroke risk: a New Target for Prevention. Stroke. 2021;52:2697–706.PubMedCrossRef

46.

Sharma D, Spring KJ, Bhaskar S. Neutrophil-lymphocyte ratio in acute ischemic stroke: Immunopathology, management, and prognosis. Acta Neurol Scand. 2021;144:486–99.PubMedCrossRef

47.

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.PubMedPubMedCentralCrossRef

48.

Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785–805.PubMedCrossRef

49.

Granelli-Piperno A, Vassalli JD, Reich E. Secretion of plasminogen activator by human polymorphonuclear leukocytes. Modulation by glucocorticoids and other effectors. J Exp Med. 1977;146:1693–706.PubMedCrossRef

50.

Song SY, Zhao XX, Rajah G, Hua C, Kang RJ, Han YP, Ding YC, Meng R. Clinical significance of baseline neutrophil-to-lymphocyte ratio in patients with ischemic stroke or hemorrhagic stroke: an updated Meta-analysis. Front Neurol. 2019;10:1032.PubMedPubMedCentralCrossRef

Title: Association between inflammatory biomarkers and venous thromboembolism: a systematic review and meta-analysis
Authors: Jiayue Ding
Xuanye Yue
Xiaobing Tian
Zhangyuan Liao
Ran Meng
Ming Zou
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Phlebothrombosis
Venous Thrombosis
Venous Thrombosis
Biomarkers
Published in: Thrombosis Journal / Issue 1/2023
Electronic ISSN: 1477-9560
DOI: https://doi.org/10.1186/s12959-023-00526-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Assessing outcomes after thrombectomy with or without iliac vein stenting for young provoked DVT patients with iliac vein stenosis

Safety and efficacy of direct oral anticoagulation in patients with and without radiofrequency ablation of non-valvular atrial fibrillation: a multicenter retrospective cohort study

High-resolution magnetic resonance imaging-based radiomic features aid in selecting endovascular candidates among patients with cerebral venous sinus thrombosis

A case-report of the unprovoked thrombotic event in a patient with thymoma and severe FVII deficiency

The effect of recombinant versus plasma-derived von Willebrand factor on prolonged PFA closure times in ECMO patients with acquired von Willebrand syndrome – an observational study

Incidence and risk factors of venous thrombotic events in patients with interstitial lung disease during hospitalization

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials